|
Published online before print August 2, 2006, doi:10.1212/01.wnl.0000229927.12007.37)
© 2006 American Academy of Neurology Brief Communications Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastomaFrom INSERM U711 (C.C., Y.M., N.A., A.B.-A., J.-Y.D., J.T., M.S.), Biologie des Interactions Neurones and Glie, Université Pierre et Marie Curie, Faculté de Médecine, and Groupe Hospitalier Pitié-Salpêtrière, and Service de Neurologie Mazarin (F.L.-D., A.B.-A., J.L., G.K., Y.-Y.D., M.S.), Hôpital de la Salpêtrière, Paris, France. Address correspondence and reprint requests to Dr. M. Sanson, Service de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière, 47 boulevard de lHôpital, 75013 Paris, France; e-mail: marc.sanson{at}psl.ap-hop-paris.fr We investigated two polymorphisms of the epidermal growth factor receptor promoter as potential risk factors and prognostic markers for glioblastoma. The 216T allele (which results in a 30% higher activity) was more frequent in the patients compared with the control population (224/376 = 59.6% vs 165/352 = 46.8%; p = 0.0006) corresponding to an odd ratio of 1.67 (1.24; 2.25). A modest difference in median survival was also associated with the TT genotype.
This article was previously published in electronic format as an Expedited E-Pub on August 2, 2006, at www.neurology.org. Supported by the Délégation à la Recherche Clinique (AP-HP; grant no. MUL 03012) and the Ligue Nationale contre le Cancer, comité dIlle et Vilaine. Disclosure: The authors report no conflicts of interest. Received November 30, 2005. Accepted in final form April 24, 2006.
This article has been cited by other articles:
|
||||||||||||||||||||||||